Enanta Pharmaceuticals (ENTA) Registration Filing summary

Company overview and business model

• Focuses on discovering and developing small molecule drugs for virology and immunology indications using a chemistry-driven approach.

• Key virology programs include treatments for hepatitis C (HCV), respiratory syncytial virus (RSV), SARS-CoV-2, and hepatitis B (HBV).

• Immunology pipeline targets type 2 inflammatory diseases such as atopic dermatitis, urticaria, asthma, and related conditions, with initial focus on KIT, STAT6, and MRGPRX2 pathways.

• Incorporated in Delaware in 1995, with principal offices in Watertown, Massachusetts.

Financial performance and metrics

• Incorporates by reference the Annual Report on Form 10-K for the fiscal year ended September 30, 2025, and the Quarterly Report on Form 10-Q for the quarter ended December 31, 2025.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including working capital, capital expenditures, commercialization, manufacturing, R&D, regulatory affairs, clinical trials, acquisitions, investments, and potential repayment or repurchase of indebtedness or capital stock.